Mereo BioPharma Group plc (MREO) insider trading
Every open-market stock purchase and sale by Mereo BioPharma Group plc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- No open-market insider trades in the last 12 months.
- Last insider buy: Merlin C Hanson (Director), $1K, 15 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $0 (0 sales).
Recent MREO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Feb 26, 2026 | Anders Ekblom (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Jeremy Bender (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Anders Ekblom (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Deepika Pakianathan (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Daniel Shames (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Daniel Shames (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Pierre Jacquet (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Pierre Jacquet (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Michael S Wyzga (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Marc J Yoskowitz (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Marc J Yoskowitz (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Annalisa Jenkins (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Annalisa Jenkins (Insider) | Bought (not open market) | — |
| Feb 26, 2026 | Jeremy Bender (Insider) | Bought (not open market) | — |
| Feb 1, 2026 | John A. Lewicki (C-suite exec) | Bought (not open market) | — |
| Feb 1, 2026 | Christine Ann Fox (CFO) | Bought (not open market) | — |
| Feb 1, 2026 | Christine Ann Fox (CFO) | Bought (not open market) | — |
| Feb 1, 2026 | Alexandra Hughes-Wilson (Insider) | Bought (not open market) | — |
| Feb 1, 2026 | Christine Ann Fox (CFO) | Bought (not open market) | — |
| Feb 1, 2026 | Alexandra Hughes-Wilson (Insider) | Bought (not open market) | — |
| Feb 1, 2026 | John A. Lewicki (C-suite exec) | Bought (not open market) | — |
| Feb 1, 2026 | John A. Lewicki (C-suite exec) | Bought (not open market) | — |
| Feb 1, 2026 | Denise Scots-Knight (CEO) | Bought (not open market) | — |
| Feb 1, 2026 | Denise Scots-Knight (CEO) | Bought (not open market) | — |
| Feb 1, 2026 | Denise Scots-Knight (CEO) | Bought (not open market) | — |
Who's trading MREO
- Marc J Yoskowitz, Insider: other filings, last Feb 26, 2026
- Anders Ekblom, Insider: other filings, last Feb 26, 2026
- Pierre Jacquet, Insider: other filings, last Feb 26, 2026
- Annalisa Jenkins, Insider: other filings, last Feb 26, 2026
- Deepika Pakianathan, Insider: other filings, last Feb 26, 2026
- Daniel Shames, Insider: other filings, last Feb 26, 2026
- Michael S Wyzga, Insider: other filings, last Feb 26, 2026
- Jeremy Bender, Insider: other filings, last Feb 26, 2026
- Christine Ann Fox, CFO: other filings, last Feb 1, 2026
- Alexandra Hughes-Wilson, Insider: other filings, last Feb 1, 2026
- Denise Scots-Knight, CEO: other filings, last Feb 1, 2026
- John A. Lewicki, C-suite exec: other filings, last Feb 1, 2026
- Charles Sermon, General Counsel: other filings, last Feb 1, 2026
Get free alerts when an insider at Mereo BioPharma Group plc files a new trade →